Beta Drugs Limited share price
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.Read more
HealthcareDrug Manufacturers - Specialty & GenericNSE: BETAISIN INE351Y01019
16 Oct 2026, 3:29 PM IST₹1,783.00▲ 32.70 (1.87%)
- Market Cap₹ 1,807 Cr.
- Current Price₹ 1,783.00
- High / Low₹ 2,808 / 990
- Stock P/E26.3
- Book Value₹ 242
- Dividend Yield0.00 %
- ROCE17.9 %
- ROE18.80 %
- Face Value₹ 10.0
More figures (10)
- EPS (TTM)₹ 67.90
- Price / Book7.38
- OPM15.2 %
- Debt / Equity0.60
- Sales growth (4Y)19.2 %
- Profit growth (4Y)10.5 %
- Promoter holding0.0 %
- EV / EBITDA22.9
- Beta-0.37
- All-time high₹ 2,808
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| BETA | -13.65% | -21.13% | +28.59% | +15.10% | +2.03% | +23.09% | +27.52% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Beta Drugs Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,807 crore.
- It trades at 26.3 times its last 12 months' earnings and 7.4 times book value.
- Revenue grew 19.2% a year over the last 4 years, profit 10.5% a year.
- Return on equity was 18.8% and return on capital employed 17.9% in the latest year.
- Debt was 0.60 times shareholders' equity.
- The share price is 36.5% below its 52-week high and up 2.0% over one year.
- Promoters and insiders hold about 0.0%; institutions about 0.0%.
Pros
AI- Strong return on equity: 22.9% on average over the last 3 years.
- Trades at 26.3 times earnings, below its 3-year median of 39.5.
- Institutional (FII + DII) holding has risen by 7.5 points over 3 years.
Cons
AI- Promoter holding has fallen by 7.82 points over 3 years, to 58.91%.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Beta Drugs Limited
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
- Employees
- 455
- Head office
- Panchkula
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Beta Drugs | 1,783.00 | 26.3 | 1,807 | 0.00 | 16 | — | 126 | — | 17.9 | 18.8 | 7.38 | 15.2 | 0.60 | 0.00 | 385 | 19.2 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 568 | 35.00 | 4,031 | 30.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 36 Co. | 1,770.90 | 31.8 | 28,983 | 0.32 | 679 | 14.29 | 5,999 | 19.15 | 16.4 | 16.9 | 4.96 | 17.3 | 0.30 | 53.40 | 20,499 | 13.5 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions14-May-2024
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions07-Nov-2023
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions08-May-2023
- Related Party TransactionBeta Drugs Limited has informed the Exchange about related party transaction for the period ended March 202228-Apr-2022
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions26-Oct-2021
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions27-Apr-2021
- Related Party TransactionsBeta Drugs Limited has informed the Exchange about related Party Transactions19-Oct-2020
- Related Party TransactionsBeta Drugs Limited has informed the Exchange regarding Non Applicability of Regulation 23(9) of SEBI (LODR) Regulations, 2015.22-Oct-2019
- Related Party TransactionsBeta Drugs Limited has informed the Exchange that Beta Drugs Limited has informed the Exchange regarding Related Party Disclosure.20-May-2019
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 362 | 385 | 510 | |
| YOY Sales Growth % | 6.20% | ||
| 300 | 309 | 415 | |
| Material Cost % | 47% | 44% | 44% |
| Employee Cost % | 9% | 18% | 15% |
| Other Expenses % | 23% | 18% | 21% |
| Operating Profit | 62 | 76 | 95 |
| OPM % | 17% | 20% | 19% |
| Other Income | 6 | 11 | 13 |
| Interest | 7 | 15 | 18 |
| Depreciation | 17 | ||
| Profit before tax | 57 | 54 | 76 |
| 26% | 24% | 24% | |
| Current tax | 15 | 14 | |
| Deferred tax | -0 | -1 | |
| 41 | |||
| Minority share | -1 | ||
| EPS in Rs | 42.02 | 40.92 | 79.49 |
Compounded Sales Growth
- TTM:
- 0%
Stock Price CAGR
- 5 Years:
- 28%
- 3 Years:
- 23%
- 1 Year:
- 2%
Return on Equity
- 4 Years:
- 23%
- Last Year:
- 19%
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 220 | 225 | 281 | |
| YOY Sales Growth % | 2.38% | ||
| 196 | 197 | 247 | |
| Material Cost % | 54% | 54% | 53% |
| Employee Cost % | 9% | 15% | 13% |
| Other Expenses % | 23% | 18% | 20% |
| Operating Profit | 24 | 29 | 34 |
| OPM % | 11% | 13% | 12% |
| Other Income | 6 | 11 | 13 |
| Interest | 5 | 12 | 13 |
| Depreciation | 10 | ||
| Profit before tax | 21 | 18 | 26 |
| 26% | 21% | 22% | |
| Current tax | 6 | 4 | |
| Deferred tax | -0 | -0 | |
| Net Profit | 14 | ||
| EPS in Rs | 15.29 | 14.14 | 25.41 |
Compounded Sales Growth
- TTM:
- 0%
Stock Price CAGR
- 5 Years:
- 28%
- 3 Years:
- 23%
- 1 Year:
- 2%
Return on Equity
- 4 Years:
- 23%
- Last Year:
- 19%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 113 | 148 | 187 | 235 |
| 20 | 15 | 138 | 148 | |
| Long term borrowings | 7 | 6 | 127 | 133 |
| Short term borrowings | 13 | 9 | 11 | 14 |
| 55 | 82 | 101 | 103 | |
| Trade payables | 40 | 59 | 71 | 81 |
| Current liabilities | 63 | 85 | 103 | 108 |
| Total Liabilities | 198 | 254 | 436 | 496 |
| 62 | 67 | 91 | 126 | |
| Gross block | 98 | 110 | 146 | 196 |
| Accumulated depreciation | 36 | 43 | 55 | 70 |
| Goodwill & intangibles | 5 | 5 | 9 | 10 |
| CWIP | 4 | 8 | 11 | 11 |
| 132 | 179 | 334 | 359 | |
| Inventories | 31 | 50 | 60 | 74 |
| Trade receivables | 63 | 79 | 103 | 119 |
| Cash & equivalents | 19 | 29 | 147 | 125 |
| Current assets | 128 | 178 | 320 | 335 |
| Total Assets | 198 | 254 | 436 | 496 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 23 | 31 | 36 | 37 | |
| Profit for the year | 31 | 36 | 42 | 41 |
| Working capital changes | -20 | -14 | -19 | -27 |
| -19 | -14 | -36 | -51 | |
| Fixed assets purchased | -18 | -12 | -37 | -53 |
| Investments sold | 1 | |||
| -2 | -7 | 118 | -8 | |
| Interest paid | -2 | -3 | -7 | -15 |
| Net Cash Flow | 2 | 9 | 118 | -22 |
| Free Cash Flow | 5 | 19 | -1 | -16 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 25.0% | 26.0% | 24.0% | 18.8% |
| ROCE | — | 32.0% | 30.4% | 19.1% | 17.9% |
| Operating margin | — | 18.9% | 17.0% | 17.1% | 15.2% |
| Net margin | — | 13.5% | 12.3% | 11.7% | 10.8% |
| Debt / equity | — | 0.17 | 0.09 | 0.70 | 0.60 |
| Current ratio | — | 2.03 | 2.10 | 3.12 | 3.10 |
| Debtor days | — | 101 | 98 | 103 | 113 |
| Inventory days | — | 86 | 100 | 124 | 152 |
| Days payable | — | 113 | 119 | 147 | 164 |
| Cash conversion cycle | — | 74 | 79 | 80 | 101 |
| Working capital days | — | 104 | 115 | 219 | 215 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 58.91%
- FIIs 1.37%
- DIIs 6.45%
- Public 33.27%
| % | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% | 58.91% |
| 0.32% | 0.32% | 0.90% | 1.16% | 1.15% | 0.90% | 0.90% | 0.90% | 1.14% | 1.16% | 1.02% | 1.37% | |
| Foreign portfolio investors (Cat. I) | 0.34% | 0.41% | 0.41% | 0.16% | 0.16% | 0.16% | 0.39% | 0.42% | 0.36% | 0.36% | ||
| Foreign portfolio investors (Cat. II) | 0.32% | 0.32% | 0.56% | 0.74% | 0.74% | 0.74% | 0.74% | 0.74% | 0.75% | 0.74% | 0.66% | 1.01% |
| 0.02% | 0.06% | 0.12% | 0.16% | 0.17% | 0.17% | 0.26% | 0.29% | 1.90% | 2.15% | 6.23% | 6.45% | |
| Alternative investment funds | 0.04% | 0.10% | 0.15% | 0.15% | 0.15% | 0.24% | 0.28% | 1.88% | 2.14% | 6.22% | 6.44% | |
| 32.92% | 32.87% | 32.25% | 31.95% | 31.95% | 32.20% | 32.11% | 32.07% | 32.07% | 32.06% | 33.65% | 33.27% | |
| Retail (up to ₹2 lakh) | 12.40% | 12.67% | 12.66% | 12.61% | 12.55% | 12.65% | 12.86% | 13.15% | 13.06% | 13.25% | 12.84% | 13.19% |
| HNIs (above ₹2 lakh) | 9.93% | 9.68% | 9.30% | 9.10% | 9.05% | 9.16% | 8.89% | 8.66% | 8.72% | 8.71% | 11.46% | 8.81% |
| NRIs | 1.17% | 1.16% | 0.98% | 1.04% | 1.05% | 1.08% | 1.01% | 1.00% | 0.97% | 0.96% | 0.94% | 0.95% |
| Bodies corporate | 8.69% | 8.65% | 8.60% | 8.53% | 8.57% | 8.56% | 8.65% | 8.55% | 8.54% | 8.54% | 7.84% | 7.79% |
| No. of Shareholders | 1,928 | 2,116 | 2,323 | 2,567 | 2,882 | 3,054 | 3,139 | 3,184 | 3,694 | 4,736 | 7,359 | 10,145 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Beta Drugs
| Holder (above 1%) | Stake |
|---|---|
| Healthquad Trust IiAIF | 4.28% |
| Airavat Capital Trust - Airavat Capital Trust IiAIF | 1.59% |
As named in the shareholding pattern for Sep 2026 filed with NSE. Shareholders below 1% are not named in the filing.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Beta Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201806-Oct-2026
- Shareholders meetingBeta Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regard…01-Oct-2026
- Trading WindowBeta Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201530-Sep-2026
- Shareholders meetingBeta Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 202630-Sep-2026
- General UpdatesBeta Drugs Limited has informed the Exchange about Azerbaijan Oncology Market Regulatory & Commercialisation update22-Sep-2026
- Copy of Newspaper PublicationBeta Drugs Limited has informed the Exchange about Copy of Newspaper Publication07-Sep-2026
- Shareholders meetingBeta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 202605-Sep-2026
- General UpdatesBeta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed …03-Sep-2026
- Shareholders meetingBeta Drugs Limited has informed the Exchange regarding Notice of undefined to be held on September 30, 202603-Sep-2026
- Outcome of Board MeetingBeta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.03-Sep-2026
- Outcome of Board MeetingBeta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 18, 2026.18-Aug-2026
- Monitoring Agency ReportMonitoring Agency Report for the Quarter ended 30th June, 202614-Aug-2026
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Schedule of meet16-Oct-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Schedule of meet16-Oct-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Schedule of meet10-Sep-2026
- Investor PresentationBeta Drugs Limited has informed the Exchange about Investor Presentation27-Jul-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Transcript22-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Link of Recording15-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Presentation15-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Schedule of meet12-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesBeta Drugs Limited has informed the Exchange about Schedule of meet12-Dec-2025
- General UpdatesBeta Drugs Limited has informed the Exchange about Intimation of Cancellation of Analyst / Institutional Investor Meeting scheduled on 10th December, 2025 under the SEBI (Listing …08-Dec-2025
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
- Beta Drugs (NSE:BETA) Ticks All The Boxes When It Comes To Earnings GrowthSimply Wall Street · 2 d ago
- Beta Drugs (NSE:BETA): What Does the Q2 FY27 Demat Confirmation Certificate Mean?Kalkine India · 6 Oct 2026
- Beta (BETA.NS) Stock Analysis: Flat at ₹2055.00, What's Next 2026-10-02 - Put Flow Alerthttps://www.siam.in/ · 2 Oct 2026
- Beta Drugs (NSE: BETA) Gets Azerbaijan Approval for Oncology ProductsKalkine India · 22 Sep 2026
- Beta Drugs NSE:BETA Azerbaijan Oncology Approval UpdateKalkine India · 22 Sep 2026
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Beta Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 06-Oct-2026
- Shareholders meetingBeta Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regard…NSE filing · 01-Oct-2026
- Trading WindowBeta Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 30-Sep-2026
- Shareholders meetingBeta Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026NSE filing · 30-Sep-2026
- General UpdatesBeta Drugs Limited has informed the Exchange about Azerbaijan Oncology Market Regulatory & Commercialisation updateNSE filing · 22-Sep-2026
- Copy of Newspaper PublicationBeta Drugs Limited has informed the Exchange about Copy of Newspaper PublicationNSE filing · 07-Sep-2026
- Shareholders meetingBeta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026NSE filing · 05-Sep-2026
- General UpdatesBeta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed …NSE filing · 03-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Beta Drugs Limited
What is the share price of Beta Drugs Limited today?
Beta Drugs Limited (BETA) last traded at ₹1,783.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of Beta Drugs Limited?
About ₹1,807 crore at the latest price.
What is the P/E ratio of Beta Drugs Limited?
About 26.3 times its earnings over the last 12 months.
Is Beta Drugs Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy Beta Drugs Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Experts are available Mon–Sat, 10 AM – 7 PM
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.